Cindy Patinote

Montpellier, 34090, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

The Novel Imiqualine EAPB02303 Is a Potent Drug for Treating Acute Myeloid Leukemia.

The Novel Imiqualine EAPB02303 Is a Potent Drug for Treating Acute Myeloid Leukemia.

Journal: Biomolecules

Published: March 25, 2025

Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer models.

Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer models.

Journal: Cell death & disease

Published: November 26, 2024

Imiquimod Reverses Chronic Toxoplasmosis-Associated Behavioral and Neurocognitive Anomalies in a Rat Model.

Imiquimod Reverses Chronic Toxoplasmosis-Associated Behavioral and Neurocognitive Anomalies in a Rat Model.

Journal: Biomedicines

Published: May 14, 2024

[1,2,4]triazolo[4,3-a]quinoxaline as Novel Scaffold in the Imiqualines Family: Candidates with Cytotoxic Activities on Melanoma Cell Lines.

[1,2,4]triazolo[4,3-a]quinoxaline as Novel Scaffold in the Imiqualines Family: Candidates with Cytotoxic Activities on Melanoma Cell Lines.

Journal: Molecules (Basel, Switzerland)

Published: June 27, 2023

Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action.

Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action.

Journal: European journal of medicinal chemistry

Published: September 17, 2020

Substantial Cellular Penetration of Fluorescent Imidazoquinoxalines.

Substantial Cellular Penetration of Fluorescent Imidazoquinoxalines.

Journal: Journal of fluorescence

Published: June 15, 2020

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.

Journal: European journal of medicinal chemistry

Published: February 13, 2020

Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications.

Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications.

Journal: Current medicinal chemistry

Published: July 19, 2019

Novel and Selective TLR7 Antagonists among the Imidazo[1,2-a]pyrazines, Imidazo[1,5-a]quinoxalines, and Pyrazolo[1,5-a]quinoxalines Series.

Novel and Selective TLR7 Antagonists among the Imidazo[1,2-a]pyrazines, Imidazo[1,5-a]quinoxalines, and Pyrazolo[1,5-a]quinoxalines Series.

Journal: Journal of medicinal chemistry

Published: July 09, 2019

Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells.

Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells.

Journal: Molecules (Basel, Switzerland)

Published: October 30, 2018

Fluorescence Study of Imidazoquinoxalines.

Fluorescence Study of Imidazoquinoxalines.

Journal: Journal of fluorescence

Published: January 19, 2017

Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.

Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.

Journal: European journal of medicinal chemistry

Published: November 03, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026